101. Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol
- Author
-
Fu, Yue, Estoppey, David, Roggo, Silvio, Pistorius, Dominik, Fuchs, Florian, Studer, Christian, Ibrahim, Ashraf S, Aust, Thomas, Grandjean, Frederic, Mihalic, Manuel, Memmert, Klaus, Prindle, Vivian, Richard, Etienne, Riedl, Ralph, Schuierer, Sven, Weber, Eric, Hunziker, Jürg, Petersen, Frank, Tao, Jianshi, and Hoepfner, Dominic
- Subjects
Biochemistry and Cell Biology ,Biomedical and Clinical Sciences ,Biological Sciences ,Microbiology ,Medical Microbiology ,Infectious Diseases ,Genetics ,Infection ,Animals ,Antifungal Agents ,Cell Proliferation ,Disease Models ,Animal ,Fermentation ,Genes ,Reporter ,Glycosylphosphatidylinositols ,Glycosyltransferases ,HCT116 Cells ,Hep G2 Cells ,Humans ,Hydrogen-Ion Concentration ,Inhibitory Concentration 50 ,K562 Cells ,Lung ,Male ,Mice ,Mice ,Inbred ICR ,Mucorales ,Multigene Family ,Polyketides ,Rhizopus ,Saccharomyces cerevisiae ,Saccharomyces cerevisiae Proteins - Abstract
Biosynthesis of glycosylphosphatidylinositol (GPI) is required for anchoring proteins to the plasma membrane, and is essential for the integrity of the fungal cell wall. Here, we use a reporter gene-based screen in Saccharomyces cerevisiae for the discovery of antifungal inhibitors of GPI-anchoring of proteins, and identify the oligocyclopropyl-containing natural product jawsamycin (FR-900848) as a potent hit. The compound targets the catalytic subunit Spt14 (also referred to as Gpi3) of the fungal UDP-glycosyltransferase, the first step in GPI biosynthesis, with good selectivity over the human functional homolog PIG-A. Jawsamycin displays antifungal activity in vitro against several pathogenic fungi including Mucorales, and in vivo in a mouse model of invasive pulmonary mucormycosis due to Rhyzopus delemar infection. Our results provide a starting point for the development of Spt14 inhibitors for treatment of invasive fungal infections.
- Published
- 2020